By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: SEC Lawsuit Against FDA Chemist for Insider Trading
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > SEC Lawsuit Against FDA Chemist for Insider Trading
Business

SEC Lawsuit Against FDA Chemist for Insider Trading

BarbaraDuck
BarbaraDuck
Share
2 Min Read
SHARE

Insider trading issues seem to reach all levels of society and not just those working in the financial areas of business. I guess when you stop and think if you are working as a chemist and have this type of information ahead of time, it could be tempting. The article continues on to say that he did not use his or his wife’s account but rather seven accounts held by other individuals but eventually the money made it back to the chemist’s account. He profited from investing ahead on 19 investments and sold other short before the negatives reached the general news. No kickback mentioned, he just seemed to be on his own investment path here. Darn it’s getting harder for the FDA to keep folks these days. BD

The Securities and Exchange Commission sued a U.S. Food and Drug Administration chemist, claiming he reaped $3.6 million from trading on confidential information related to drug-approval applications. Cheng Yi Liang, 57, made trades involving 19 companies from as early as July 2006 in advance of at least 27 announcements of FDA decisions on drug applications, the SEC said in a lawsuit filed today at U.S. District Court in Greenbelt, Maryland. The chemist, who worked for the FDA’s Center for Drug Evaluation and Research, violated his duty as a federal employee not to engage in financial transactions using nonpublic government information and not to use such information for his personal benefit, according to the SEC, which is seeking disgorgement of illegal profits and unspecified fines.

TAGGED:FDAhealth care law
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

pay per click advertising
BusinessFinance

Wallet Burn and the Nasty Side of Pay-per-Click Advertising

April 25, 2015

The Age of “Patient Opinion Leaders”

March 25, 2014

Health Care Buzz Today

June 29, 2011

HOW MUCH IS THAT? I’m not the only one who thinks that’s a great healthcare question …

November 13, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?